Skip to Content

Generic Relpax Availability

Relpax is a brand name of eletriptan, approved by the FDA in the following formulation(s):

RELPAX (eletriptan hydrobromide - tablet;oral)

Has a generic version of Relpax been approved?

A generic version of Relpax has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Relpax and have been approved by the FDA:

eletriptan hydrobromide tablet;oral

  • Manufacturer: AJANTA PHARMA LTD
    Approval date: August 29, 2017
    Strength(s): [AB], [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: August 11, 2017
    Strength(s): [AB], [AB]
  • Manufacturer: TEVA PHARMS USA
    Approval date: June 27, 2017
    Strength(s): [AB], [AB]
  • Manufacturer: ZYDUS PHARMS USA INC
    Approval date: June 16, 2017
    Strength(s): [AB], [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Relpax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Indole derivatives
    Patent 5,545,644
    Issued: August 13, 1996
    Inventor(s): Macor; John E. & Wythes; Martin J.
    Assignee(s): Pfizer Inc.
    Compounds of the formula ##STR1## wherein n is 0, 1, or 2; X is hydrogen, chlorine, bromine or iodine; R.sub.1 is hydrogen; R.sub.3 is selected from hydrogen and C.sub.1 to C.sub.6 linear or branched alkyl; and R.sub.2 is as defined in the specification and the pharmaceutically acceptable salts thereof are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators. A process for forming indoles by transition metal catalyzed cyclization of a dihalogenated intermediate is also disclosed.
    Patent expiration dates:
    • December 26, 2016
      Drug substance
      Drug product
  • Salts of an anti-migraine indole derivative
    Patent 6,110,940
    Issued: August 29, 2000
    Inventor(s): Harding; Valerie Denise & Macrae; Ross James & Ogilvie; Ronald James
    Assignee(s): Pfizer Inc.
    The present invention relates to hydrobromide salts of 3-(N-methyl-2(R)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethyl)-1H-indole having the formula (I): ##STR1##
    Patent expiration dates:
    • August 29, 2017
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.